19-45 岁成年人的人乳头瘤病毒疫苗接种率：2017 年国家健康访谈调查分析。
Human Papillomavirus Vaccination Prevalence Among Adults Aged 19-45 Years: An Analysis of the 2017 National Health Interview Survey.
机构信息
Department of Public Health, Purdue University, West Lafayette, Indiana; Cancer Prevention and Control Program, Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana.
Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida; Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, Florida.
出版信息
Am J Prev Med. 2020 Dec;59(6):837-849. doi: 10.1016/j.amepre.2020.05.031. Epub 2020 Nov 5.
INTRODUCTION
In 2018, the U.S. Food and Drug Administration extended the licensure for human papillomavirus vaccination to include everyone aged 27-45 years. In 2019, the Advisory Committee on Immunization Practices issued a recommendation that adults aged 27-45 years and their providers engage in shared clinical decision making about human papillomavirus vaccination. In addition, in 2019, the Advisory Committee on Immunization Practices reiterated that all previously unvaccinated individuals receive catch-up vaccination through age 26 years. This study estimates the pre-recommendation prevalence of human papillomavirus vaccination and factors associated with vaccination in 2 age groups (19-26 years [young adults] and 27-45 years [mid-adults]), forming a baseline to monitor future coverage among U.S. adults.
METHODS
The final sample included 9,744 individuals (2,522 young adults and 7,222 mid-adults) who participated in the 2017 National Health Interview Survey. The main outcomes were receipt of 1 or more human papillomavirus vaccination and whether the participant had been vaccinated as an adult. Demographic characteristics and healthcare factors were included as covariates in statistical analyses.
RESULTS
Population estimate of receiving 1 or more human papillomavirus vaccine doses among young adults was 36.3% (female: 51.5%, male: 21.2%; p<0.001) and 9.7% for mid-adults (females: 15.8%, males: 3.2%; p<0.001). In the best-fit model, age was inversely associated with vaccination for mid-adults (female: OR=0.84, 95% CI=0.81, 0.86; male: OR=0.86; 95% CI=0.82, 0.90) and male young adults (OR=0.79, 95% CI=0.71, 0.88). Of the entire vaccinated sample aged 19-45 years, 26.6% had received their first vaccination as an adult (95% CI=23.9, 29.4).
CONCLUSIONS
These data emphasize the continued need for vaccinating adolescents aged 11-12 years given that few adults were vaccinated against human papillomavirus.
简介
2018 年，美国食品和药物管理局将人乳头瘤病毒疫苗接种的许可范围扩大到所有 27-45 岁的人群。2019 年，免疫实践咨询委员会发布了一项建议，即 27-45 岁的成年人及其提供者就人乳头瘤病毒疫苗接种进行共同的临床决策。此外，2019 年，免疫实践咨询委员会重申，所有以前未接种疫苗的人应在 26 岁之前补种疫苗。本研究旨在估计推荐前人乳头瘤病毒疫苗接种的流行率，并分析与疫苗接种相关的因素，该研究对象为 2 个年龄组（19-26 岁[年轻人]和 27-45 岁[中年人]），为监测未来美国成年人的疫苗接种覆盖率提供基线数据。
方法
最终样本包括 9744 名参与者（2522 名年轻人和 7222 名中年人），他们参加了 2017 年全国健康访谈调查。主要结果是接受了 1 剂或多剂人乳头瘤病毒疫苗接种以及参与者是否作为成年人接种了疫苗。在统计分析中，将人口统计学特征和医疗保健因素作为协变量。
结果
年轻人中接种 1 剂或多剂人乳头瘤病毒疫苗的人群估计数为 36.3%（女性：51.5%，男性：21.2%；p<0.001），中年人为 9.7%（女性：15.8%，男性：3.2%；p<0.001）。在最佳拟合模型中，年龄与中年人的疫苗接种呈负相关（女性：OR=0.84，95%CI=0.81，0.86；男性：OR=0.86；95%CI=0.82，0.90）和年轻男性（OR=0.79，95%CI=0.71，0.88）。在 19-45 岁的整个已接种疫苗人群中，有 26.6%的人作为成年人首次接种疫苗（95%CI=23.9，29.4）。
结论
鉴于很少有成年人接种人乳头瘤病毒疫苗，这些数据强调了继续为 11-12 岁青少年接种疫苗的必要性。
Zotero 插件